Repare Therapeutics Announces Pretreated Patients On Lunresertib And Camonsertib Combination Achieved 25.9% Overall Response Rate In Endometrial Cancer And 37.5% In Platinum-Resistant Ovarian Cancer
Repare Therapeutics Announces Pretreated Patients On Lunresertib And Camonsertib Combination Achieved 25.9% Overall Response Rate In Endometrial Cancer And 37.5% In Platinum-Resistant Ovarian Cancer
Repare Therapeutics 宣布髓外患者在 Lunresertib 和 Camonsertib 组合治疗下，子宫内膜癌的总体反应率达 25.9%，铂金耐药卵巢癌的总体反应率为 37.5%。
Repare Therapeutics Announces Pretreated Patients On Lunresertib And Camonsertib Combination Achieved 25.9% Overall Response Rate In Endometrial Cancer And 37.5% In Platinum-Resistant Ovarian Cancer
Repare Therapeutics 宣布髓外患者在 Lunresertib 和 Camonsertib 组合治疗下，子宫内膜癌的总体反应率达 25.9%，铂金耐药卵巢癌的总体反应率为 37.5%。
热门讨论
特斯拉绩后巨震，后市你怎么看？
特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？
Moo Earnings
01/24 10:26
TSLA财报预告：通过猜测开盘价来获取奖励！